Skip to content
2000
Volume 3, Issue 10
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Inhibition of thrombin receptor (PAR-1) is a promising therapeutic approach for the treatment of various cardiovascular disorders such as unstable angina, acute myocardial infarction, stroke, and restenosis. Since a PAR- 1 antagonist is specific for the cellulalr actions of thrombin, and does not interfere with fibrin generation, it is expected to have less bleeding liability than the currently available treatments. Several peptide and non-peptide PAR-1 antagonists with potent inhibition of platelet aggregation have been reported. Antithrombotic effect of a PAR-1 antibody has been demonstrated in a baboon thrombosis model and the antirestenosis property of a PAR-1 antagonist has been demonstrated in a rat model.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026033452122
2003-06-01
2025-05-13
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026033452122
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test